VisionGate Raises $2M, Partners on Technology for Lung Cancer Testing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – VisionGate today announced it has raised $1.96 million in the first tranche of a financing round and forged two collaborations to evaluate its automated 3D cell imaging platform for the early detection of lung cancer.

The $1.96 million tranche is part of a targeted $3 million equity round and will be used for further clinical development of its technology. Participants included undisclosed new and existing investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.